Latest for Nocion

Highlight

Endpoints News: Nocion raises $62M for different approach to chronic cough than Merck, GSK

In the middle of 2023, Richard Batycky told a couple of his fellow executives at Nocion Therapeutics to consider looking for roles elsewhere. He...
Highlight

FierceBiotech: Nocion Therapeutics named to Fierce 15

While whole shoals of biotechs are clustered around single cancer targets, Nocion is away from the pack working on better ways to treat conditions...
Highlight

Julie Grant: Announcing Nocion Therapeutics, a novel approach to neurogenic inflammation

Today, Canaan proudly introduces Nocion Therapeutics, a Series A neurogenic inflammation and analgesic company discovering and developing novel...